{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:02:37Z","timestamp":1793714557297,"version":"4.6.1"},"reference-count":37,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011898","name":"Marianne and Marcus Wallenberg Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-02189"],"award-info":[{"award-number":["2021-02189"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-02814"],"award-info":[{"award-number":["2021-02814"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-726341"],"award-info":[{"award-number":["SLS-726341"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,2,20]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Autologous haematopoietic stem cell transplantation (AHSCT) has emerged as a highly effective treatment for relapsing-remitting multiple sclerosis (RRMS), though patient selection remains challenging. The degree to which disease-modifying therapies (DMTs) and procedure-related complications affect treatment outcomes is unclear. The objective of this study was to investigate the factors that might influence outcomes following AHSCT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from the multicentre, retrospective cohort study Haematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden (AutoMS-Swe) were analysed, comprising 174 patients with RRMS who received AHSCT before 1 January 2020. Primary outcomes included inflammatory disease activity, confirmed disability worsening (CDW) and overall evidence of disease activity. Confirmed disability improvement was investigated as a secondary outcome. Associations between variables of interest and outcomes were assessed using univariable Cox proportional hazards models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients who received rituximab as the last DMT before AHSCT had a reduced hazard of inflammatory disease activity (HR 0.18, 95% CI 0.04 to 0.78). Epstein-Barr virus detection was associated with a higher hazard of inflammatory disease activity (HR 2.3, 95%\u2009CI 1.05 to 5.07). CDW was associated with longer disease durations (HR 1.09, 95%\u2009CI 1.00 to 1.19) and was negatively associated with gadolinium-enhancing lesions (HR 0.08, 95%\u2009CI 0.01 to 0.64). No CDW events occurred in treatment-naive patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Prior rituximab treatment appears to be protective against inflammatory activity after AHSCT. Disease duration and gadolinium-enhancing lesions are major determinants of disability following AHSCT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnnp-2024-335512","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:08:22Z","timestamp":1741331302000},"page":"966-974","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-7546","authenticated-orcid":false,"given":"Yassine","family":"Noui","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Zjukovskaja","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Silfverberg","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Center for Clinical Research Dalarna, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kultima","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-8821","authenticated-orcid":false,"given":"Andreas","family":"Tolf","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Tolf","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Division of Hematology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Division of Hematology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Burman","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2025092709451179000_96.10.966.1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.148.6.1693"},{"key":"2025092709451179000_96.10.966.2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700666"},{"key":"2025092709451179000_96.10.966.3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700944"},{"key":"2025092709451179000_96.10.966.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01702-w"},{"key":"2025092709451179000_96.10.966.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003987"},{"key":"2025092709451179000_96.10.966.6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025092709451179000_96.10.966.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-2933-6"},{"key":"2025092709451179000_96.10.966.8","first-page":"e1215","article-title":"Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis","volume":"96","author":"Boffa","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025092709451179000_96.10.966.9","first-page":"e890","article-title":"Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series","volume":"97","author":"Nicholas","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025092709451179000_96.10.966.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10820-2"},{"key":"2025092709451179000_96.10.966.11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis","volume":"80","author":"Kalincik","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025092709451179000_96.10.966.12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331864"},{"key":"2025092709451179000_96.10.966.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001329"},{"key":"2025092709451179000_96.10.966.14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"The Lancet"},{"key":"2025092709451179000_96.10.966.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003660"},{"key":"2025092709451179000_96.10.966.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18743"},{"key":"2025092709451179000_96.10.966.17","unstructured":"Autologous stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing-remitting multiple sclerosis (StarMS): ISRCTN88667898."},{"key":"2025092709451179000_96.10.966.18","unstructured":"Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting multiple sclerosis (RAM-MS): NCT03477500 ."},{"key":"2025092709451179000_96.10.966.19","unstructured":"A multicenter randomized controlled trial of best available therapy versus autologous hematopoietic stem cell transplant for treatment-resistant relapsing multiple sclerosis (ITNO77AI): NCT04047628 ."},{"key":"2025092709451179000_96.10.966.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-328797"},{"key":"2025092709451179000_96.10.966.21","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8222"},{"key":"2025092709451179000_96.10.966.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7"},{"key":"2025092709451179000_96.10.966.23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci Adv"},{"key":"2025092709451179000_96.10.966.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2025092709451179000_96.10.966.25","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511429320"},{"key":"2025092709451179000_96.10.966.26","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506071301"},{"key":"2025092709451179000_96.10.966.27","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520985238"},{"key":"2025092709451179000_96.10.966.28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332790"},{"key":"2025092709451179000_96.10.966.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0684-0"},{"key":"2025092709451179000_96.10.966.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00775-5"},{"key":"2025092709451179000_96.10.966.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00498-5"},{"key":"2025092709451179000_96.10.966.32","doi-asserted-by":"crossref","unstructured":"Schneider-Hohendorf T , W\u00fcnsch C , Falk S , et al . Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain (Bacau) 2024:awae244. doi:10.1093\/brain\/awae244","DOI":"10.1093\/brain\/awae244"},{"key":"2025092709451179000_96.10.966.33","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02308-06"},{"key":"2025092709451179000_96.10.966.34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz047"},{"key":"2025092709451179000_96.10.966.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109709"},{"key":"2025092709451179000_96.10.966.36","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000948"},{"key":"2025092709451179000_96.10.966.37","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology (ECronicon)"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:45:48Z","timestamp":1758991548000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jnnp-2024-335512"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335512","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}